Elastic-Layer Microfluidics for Closed mRNA Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current technologies for manufacturing and formulating polynucleotide therapeutics, such as mRNA, are prone to contamination and degradation, and centralized production is costly and slow, making them unsuitable for therapeutic formulations.

Innovation Solution

A microfluidic apparatus with elastic layers and contoured surfaces is used to create a closed path system that minimizes manual handling, provides a nearly aseptic environment, and integrates synthesis, purification, dialysis, and compounding processes, enabling rapid and reproducible production of therapeutic polynucleotides, including mRNA, in a single integrated apparatus.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If centralized production is used for polynucleotide therapeutics, then manufacturing scale is increased, but production time increases and contamination risk increases

Engineering Contradiction:

Improvemanufacturing scaleVSAvoidproduction time

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The production process is divided into multiple independent microfluidic modules including synthesis module, purification module with magnetic beads, dialysis module, and formulation module. Each module performs a specific function in a miniaturized format, allowing parallel processing and reducing overall production time while maintaining scalable capacity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

A closed-path microfluidic system serves as an intermediary between raw materials and final therapeutic product, enabling automated processing through integrated modules. The system includes automated sample loading, in-line purification with magnetic bead separation, and sterile filtration, eliminating manual handling steps that increase contamination risk and production time.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If manual handling is used in therapeutic production, then operational flexibility is maintained, but contamination risk increases

Engineering Contradiction:

Improveoperational flexibilityVSAvoidcontamination risk

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The microfluidic system performs self-service through automated fluid handling, magnetic bead separation, and sterile filtration. The closed-path design automatically progresses samples through synthesis, purification, dialysis, and formulation modules without manual intervention, maintaining operational flexibility through programmable control while eliminating contamination risks from manual handling.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

Manual mechanical handling operations are replaced with automated microfluidic mechanisms including pneumatic actuation for valve control, magnetic field application for bead separation, and integrated pumps for fluid transport. This substitution maintains operational flexibility through programmable control while eliminating human contact with therapeutic materials.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Manufacturing precision

If multiple processing steps are performed separately, then each process can be optimized, but production time increases and contamination risk increases

Engineering Contradiction:

Improveprocess optimizationVSAvoidproduction time

Core Design Contradiction:

Manufacturing precisionVSLoss of time

Solution Approach 1:

Multiple processing steps including synthesis, purification with magnetic beads, dialysis, and formulation are merged into a single integrated microfluidic device. The closed-path system allows these processes to occur in sequence within the same sterile environment, maintaining individual process optimization while reducing total production time and eliminating contamination risks from transfer between separate systems.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system ensures high reproducibility and rapid production of therapeutic polynucleotides with minimal contamination, allowing for patient-specific therapeutics to be produced at the point of care.

Implementation Method 1

an elastic layer disposed between the first plate and the second plate, the elastic layer having a first region and a second region, the first region corresponding to the first chamber region and the second region corresponding to the second chamber region

Methodology Applied

Scientific EffectElastic deformation: Elasticity

Implementation Method 2

the first chamber region and the second chamber region each having a contoured surface

Methodology Applied

Scientific EffectFluid flow direction through geometry: Geometry

Data Source

PatentUS20260014558A1Microfluidic apparatus with elastic layers and contoured surface

Publication Date: 2026.01.15 MEDICI THERAPEUTICS INC

AI summary

A microfluidic apparatus includes a first plate, a second plate, and a microfluidic path defined between the first plate and the second plate. The microfluidic path includes at least one chamber. The microfluidic apparatus also includes an elastic layer disposed between the first plate and the second plate. The elastic layer includes a first membrane extending across the at least one chamber. The first membrane is configured to deflect to drive a fluid through the at least one chamber. The elastic layer also includes a second membrane having at least one aperture. The at least one aperture is aligned with the at least one chamber.